Atlas Trials

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Clinical trial NCT04553393 · UNKNOWN

Trial details

NCT number
NCT04553393
Sponsor
Chinese PLA General Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
Start date
2020-09-09
Primary completion
2021-09-08
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.